Our updates during the COVID-19 pandemic

During the COVID-19 pandemic, our commitment to patients, our employees and the communities where we operate remains unchanged. We will continue to supply our medicines to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.

Every day, new questions and concerns are being raised and we want to keep you informed with updates on the supply of our medicines, answers for people who are taking them and how to get in touch with us.

 

(Last updated 6 April 2020)

 


Device assembly production, Hillerød, Denmark

 

Our continued supply of vital medicines

Currently, we are not experiencing any supply issues. We are well prepared for situations like this, and we have a storage policy that ensures long-term delivery. This is important as we are dealing with vital medicines that patients all over the world depend on every day.

We are aware that health authorities and pharmacies are doing their best to ensure the availability of vital medicines during COVID-19, and we can assure you that our current stock levels are normal. 

As we continue to monitor the situation, we will share our updates. 

If you have any questions or concerns, please contact us

 


Male wearing protection mask looking out the window

 

People living with diabetes and other serious chronic disease

If you, or someone you know, is living with diabetes, obesity, or another serious chronic disease, there is no doubt you have some concerns. As many of us are being asked to stay home, there are many questions about both physical and mental concerns.

These exceptional circumstances are raising many questions about both physical and mental concerns during this period. 

We want to share tips and suggestions we hope you will find useful. 

Learn about managing diabetes and COVID-19

Learn more about COVID-19 and obesity


Novo Nordisk employees from our production wearing safety masks

 

Contributing in the fight against COVID-19

We are using our expertise, resources and global reach to contribute to research efforts and support with much needed medical supplies. 

As new issues continue to develop, we are working in close contact with authorities and international bodies responding to the COVID-19 pandemic.

We continue to contribute where we can and keep our focus on maintaining the supply of our lifesaving medicines to people with serious chronic diseases.

See our actions and contributions

 


Pharmacy, drawer with medicine

 

Taking care of our employees

To protect the health and safety of our employees, we have asked all non-production employees to work from home until further notice.

During these extraordinary working conditions, we are ensuring employees have support to keep active, work ergonomically from home and adopt to a digital workplace.

We are taking measures to keep the number of employees working at our productions sites as low as possible and to practice recommended social distancing practices when on the job. We are asking only those employees for whom COVID-19 is not considered a health risk.

 


HCP with patient, Novo Nordisk PIONEER study

 

Status on our clinical trials

We are continuing all of our already-initiated clinical trials and we do not expect significant delays in those that are close to finalisation.

In the current situation, we are in close dialogue with trial investigators across the globe and we rely on their judgment to pause any ongoing trial recruitment and minimise patient visits to sites in order to coincide with regular medical care visits.

We also observe that trial follow-up is increasingly difficult, and we are working with relevant trial sites, investigators and authorities to find the best solutions in the situation. To reflect the current strain on the healthcare system, no new trials will be initiated.

 

Anette Vibeke Petersen is operator at Novo Nordisk in Denmark

 

Our response to COVID-19

With the COVID-19 pandemic escalating, our CEO, Lars Fruergaard Jørgensen, makes the case for resilience, collective action and learning from past experience in the face of an unprecedented challenge.

See what we learned from our production facility in China during COVID-19 while striving to maintain continuity of supply.

Here's what we learned


Frequently asked questions:
About our operations and business

Frequently asked questions:
For people living with diabetes & obesity


Contact us

In times like these, we want to help provide clarity for healthcare providers, patients, partners and others. Below you can see how to contact us with your questions or concerns:
 

Do you have questions or concerns about the supply of our medicines?
We would like to hear from you

Do you have insulin access and affordability questions?
Please get in touch with our offices in your country

Do you have other questions?
Please let us know and contact us